News
Astellas bets on Vir cancer drug, and other licensing deals
Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.
R&D
Results, reality, and recalibration: Unpacking AI hype at SC...
SCOPE 2026 was dominated by one big topic: AI. You couldn’t walk five steps without hearing about something that AI was going to fix.
News
After CagriSema blow, Novo reveals data for obesity 'triple'
Novo Nordisk's triple-action obesity therapy UBT251, licensed in a $2bn deal last year, achieved almost 20% weight loss in a mid-stage trial.
News
MSD splits pharma business, hiving off oncology
MSD is separating its cancer and non-cancer pharma operations as it prepares for the looming loss of patent protection for $31bn blockbuster Keytruda.
News
FDA maps new regulatory route for ultra-rare diseases
The FDA has sketched out its 'plausible mechanism' regulatory pathway for individualised therapies that treat ultra-rare diseases.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
